SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4hzs'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1A7Y_A_DVAA2_0 (ACTINOMYCIN D)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	4 / 4	THR A 391 PRO A 390 THR A 414 PRO A 357	None	1.27A	1a7yA-4hzsA: undetectable 1a7yC-4hzsA: undetectable	1a7yA-4hzsA: 5.99 1a7yC-4hzsA: 5.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.51A	1iepA-4hzsA: 27.6	1iepA-4hzsA: 38.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1M17_A_AQ4A999_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 ALA A 156 LYS A 158 THR A 205 LEU A 207 GLY A 211 LEU A 259 ASP A 270	None	0.72A	1m17A-4hzsA: 28.8	1m17A-4hzsA: 35.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MUO_A_ADNA1_1 (AURORA-RELATED KINASE 1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 9	LEU A 132 GLY A 133 VAL A 140 ALA A 156 ALA A 208 LEU A 259	None	0.63A	1muoA-4hzsA: 16.5	1muoA-4hzsA: 26.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1SQ5_B_PAUB6003_0 (PANTOTHENATE KINASE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 10	GLY A 436 HIS A 223 TYR A 326 LEU A 405 ILE A 416	None	1.48A	1sq5B-4hzsA: undetectable	1sq5B-4hzsA: 22.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T46_A_STIA3_1 (HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	None	0.58A	1t46A-4hzsA: 20.7	1t46A-4hzsA: 34.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	ALA A 156 THR A 205 LEU A 243 HIS A 250 GLY A 269	None	0.64A	1uwhA-4hzsA: 26.1	1uwhA-4hzsA: 29.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	ALA A 156 LYS A 158 THR A 205 LEU A 243 HIS A 250 GLY A 269	None	0.73A	1uwhB-4hzsA: 25.9	1uwhB-4hzsA: 29.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	VAL A 140 ALA A 156 THR A 205 LEU A 243 HIS A 250 GLY A 269	None	0.55A	1uwjA-4hzsA: 10.8	1uwjA-4hzsA: 29.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	VAL A 140 ALA A 156 THR A 205 LEU A 243 HIS A 250 GLY A 269	None	0.54A	1uwjB-4hzsA: 10.8	1uwjB-4hzsA: 29.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XBB_A_STIA1_1 (TYROSINE-PROTEIN KINASE SYK)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 9	LEU A 132 VAL A 140 ALA A 156 ALA A 208 GLY A 211 LEU A 259	None	0.35A	1xbbA-4hzsA: 29.7	1xbbA-4hzsA: 32.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	ALA A 156 MET A 181 THR A 205 GLY A 211 LEU A 214 ASP A 215 ARG A 218 ASP A 270 PHE A 271	None	0.95A	1xkkA-4hzsA: 21.6	1xkkA-4hzsA: 36.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	ALA A 156 THR A 205 GLY A 211 LEU A 214 ASP A 215 ARG A 218 LEU A 259 ASP A 270 PHE A 271	None	0.88A	1xkkA-4hzsA: 21.6	1xkkA-4hzsA: 36.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XKK_A_FMMA91_2 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 9	LEU A 132 VAL A 140 LYS A 158 LEU A 192 LEU A 207 LEU A 273	None	0.70A	1xkkA-4hzsA: 21.6	1xkkA-4hzsA: 36.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITO_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 ALA A 156 LYS A 158 THR A 205 GLY A 211 ASP A 215 LEU A 259	None	0.63A	2itoA-4hzsA: 29.3	2itoA-4hzsA: 36.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 GLY A 133 VAL A 140 ALA A 156 LYS A 158 GLY A 211 LEU A 259 ASP A 270	None	0.71A	2ityA-4hzsA: 29.4	2ityA-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 GLY A 133 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	None	0.73A	2ityA-4hzsA: 29.4	2ityA-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITZ_A_IREA2021_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 GLY A 211 ASP A 215 LEU A 259 ASP A 270	None	0.53A	2itzA-4hzsA: 22.9	2itzA-4hzsA: 36.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITZ_A_IREA2021_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 ASP A 215 LEU A 259	None	0.66A	2itzA-4hzsA: 22.9	2itzA-4hzsA: 36.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2XP2_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 9	LEU A 132 VAL A 140 ALA A 156 GLY A 211 LEU A 259 GLY A 269	None	0.38A	2xp2A-4hzsA: 28.8	2xp2A-4hzsA: 33.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_C_B49C1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 10	VAL A 140 ALA A 156 ILE A 190 GLY A 211 ASP A 215 LEU A 259	None	0.72A	2y7jC-4hzsA: 22.2	2y7jC-4hzsA: 21.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_C_B49C1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 10	VAL A 140 ALA A 156 LEU A 207 GLY A 211 ASP A 215 LEU A 259	None	0.66A	2y7jC-4hzsA: 22.2	2y7jC-4hzsA: 21.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_D_B49D1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 10	VAL A 140 ALA A 156 ILE A 190 GLY A 211 ASP A 215 LEU A 259	None	0.66A	2y7jD-4hzsA: 22.4	2y7jD-4hzsA: 21.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_D_B49D1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 10	VAL A 140 ALA A 156 LEU A 207 GLY A 211 ASP A 215 LEU A 259	None	0.58A	2y7jD-4hzsA: 22.4	2y7jD-4hzsA: 21.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 10	LEU A 132 ALA A 156 LYS A 158 LEU A 207 GLY A 211 LEU A 259	None	0.66A	3aoxA-4hzsA: 19.4	3aoxA-4hzsA: 32.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	VAL A 140 ALA A 156 MET A 181 LEU A 192 GLY A 211 LEU A 259 ASP A 270 PHE A 271 LEU A 273	None	0.53A	3bbtB-4hzsA: 23.7	3bbtB-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	VAL A 140 ALA A 156 MET A 181 LEU A 192 LEU A 207 GLY A 211 LEU A 259 ASP A 270 LEU A 273	None	0.73A	3bbtB-4hzsA: 23.7	3bbtB-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	VAL A 140 ALA A 156 MET A 181 LEU A 192 THR A 205 GLY A 211 LEU A 259 ASP A 270 PHE A 271	None	0.69A	3bbtB-4hzsA: 23.7	3bbtB-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	VAL A 140 ALA A 156 MET A 181 LEU A 192 THR A 205 LEU A 207 GLY A 211 LEU A 259 ASP A 270	None	0.84A	3bbtB-4hzsA: 23.7	3bbtB-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BBT_D_FMMD91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	VAL A 140 ALA A 156 LYS A 158 GLY A 211 LEU A 259 ASP A 270 PHE A 271 LEU A 273	None	0.65A	3bbtD-4hzsA: 23.2	3bbtD-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BBT_D_FMMD91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	VAL A 140 ALA A 156 MET A 181 THR A 205 GLY A 211 LEU A 259 ASP A 270 PHE A 271 LEU A 273	None	0.85A	3bbtD-4hzsA: 23.2	3bbtD-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 GLY A 133 ALA A 156 LYS A 158 GLY A 211 LEU A 259	None	0.47A	3c7qA-4hzsA: 27.2	3c7qA-4hzsA: 31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	ALA A 156 LEU A 189 GLY A 211 PHE A 248 HIS A 250 LEU A 259	None	0.61A	3cs9A-4hzsA: 27.5	3cs9A-4hzsA: 35.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	ALA A 156 LEU A 189 GLY A 211 PHE A 248 HIS A 250	None	0.50A	3cs9D-4hzsA: 26.6	3cs9D-4hzsA: 35.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	ALA A 156 LEU A 189 THR A 205 GLY A 211 HIS A 250	None	0.64A	3cs9D-4hzsA: 26.6	3cs9D-4hzsA: 35.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EYG_A_MI1A1_1 (TYROSINE-PROTEIN KINASE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	LEU A 132 GLY A 133 GLY A 135 GLY A 138 VAL A 140 ALA A 156 LYS A 158 SER A 212 LEU A 259	None	0.80A	3eygA-4hzsA: 27.1	3eygA-4hzsA: 31.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EYG_A_MI1A1_1 (TYROSINE-PROTEIN KINASE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	LEU A 132 GLY A 135 GLY A 138 VAL A 140 ALA A 156 LYS A 158 SER A 212 ASN A 257 LEU A 259	None	0.97A	3eygA-4hzsA: 27.1	3eygA-4hzsA: 31.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0E_A_B49A9000_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 11	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.58A	3g0eA-4hzsA: 26.0	3g0eA-4hzsA: 32.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0F_A_B49A9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 11	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.62A	3g0fA-4hzsA: 18.4	3g0fA-4hzsA: 32.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0F_B_B49B9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 10	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.57A	3g0fB-4hzsA: 27.1	3g0fB-4hzsA: 32.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.46A	3ms9B-4hzsA: 27.2	3ms9B-4hzsA: 38.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.54A	3mssB-4hzsA: 27.4	3mssB-4hzsA: 38.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	None	0.60A	3octA-4hzsA: 27.4	3octA-4hzsA: 32.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OHT_A_1N1A1000_1 (P38A)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	GLY A 133 VAL A 140 ALA A 156 ILE A 190 THR A 205 LEU A 259	None	1.00A	3ohtA-4hzsA: 5.2	3ohtA-4hzsA: 24.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OHT_A_1N1A1000_1 (P38A)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	GLY A 133 VAL A 140 ALA A 156 LYS A 158 ILE A 190 THR A 205	None	0.77A	3ohtA-4hzsA: 5.2	3ohtA-4hzsA: 24.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OHT_A_1N1A1000_1 (P38A)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	GLY A 133 VAL A 140 ALA A 156 LYS A 158 THR A 205 ASP A 270	None	0.77A	3ohtA-4hzsA: 5.2	3ohtA-4hzsA: 24.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OHT_B_1N1B1000_1 (P38A)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	GLY A 133 VAL A 140 ALA A 156 THR A 205 GLY A 211	None	0.53A	3ohtB-4hzsA: 4.9	3ohtB-4hzsA: 24.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_B_1N1B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259 ASP A 270	None	0.62A	3qlgB-4hzsA: 20.0	3qlgB-4hzsA: 36.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3QPS_A_CHDA211_0 (CMER)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 10	LEU A 258 PHE A 378 ALA A 237 GLY A 239 ILE A 268	None	1.39A	3qpsA-4hzsA: undetectable	3qpsA-4hzsA: 17.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.40A	3sxrA-4hzsA: 16.7	3sxrA-4hzsA: 39.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.38A	3sxrB-4hzsA: 27.6	3sxrB-4hzsA: 39.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 LEU A 207 GLY A 211 ASP A 215 LEU A 259	None	0.64A	3ug2A-4hzsA: 23.3	3ug2A-4hzsA: 35.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	LEU A 132 VAL A 140 ALA A 156 GLY A 211 PHE A 271	None	0.50A	3wzdA-4hzsA: 28.3	3wzdA-4hzsA: 33.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZBF_A_VGHA3000_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 ALA A 156 LEU A 207 GLY A 211 LEU A 259 GLY A 269	None	0.58A	3zbfA-4hzsA: 28.6	3zbfA-4hzsA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 GLY A 211 LEU A 259	None	0.43A	4agcA-4hzsA: 27.0	4agcA-4hzsA: 30.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4DU2_B_LDPB501_1 (CYTOCHROME P450 BM3 VARIANT B7)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	4 / 7	ALA A 298 ALA A 369 ALA A 310 THR A 313	None	0.79A	4du2B-4hzsA: undetectable	4du2B-4hzsA: 23.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259 ASP A 270	None	0.70A	4hjoA-4hzsA: 32.4	4hjoA-4hzsA: 35.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4I22_A_IREA9001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	LEU A 132 GLY A 133 VAL A 140 ALA A 156 LYS A 158 GLY A 211 ASP A 215 LEU A 259 ASP A 270	None	0.67A	4i22A-4hzsA: 24.8	4i22A-4hzsA: 35.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IFG_A_1E8A601_1 (CALMODULIN-DOMAIN PROTEIN KINASE 1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	GLY A 133 VAL A 140 ALA A 156 LYS A 158 LEU A 192 LEU A 259 LEU A 273	None	0.74A	4ifgA-4hzsA: 23.6	4ifgA-4hzsA: 24.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4LMN_A_EUIA503_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	LYS A 158 ASN A 257 ASP A 270 PHE A 271 GLY A 272	None	0.84A	4lmnA-4hzsA: 23.4	4lmnA-4hzsA: 25.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MKC_A_4MKA1503_1 (ALK TYROSINE KINASE RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	LEU A 132 GLY A 135 VAL A 140 ALA A 156 LYS A 158 LEU A 207 GLY A 211 LEU A 259 ASP A 270	None	0.85A	4mkcA-4hzsA: 28.8	4mkcA-4hzsA: 33.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MM4_B_8PRB603_2 (TRANSPORTER)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	3 / 3	SER A 311 MET A 315 ASP A 344	None	0.93A	4mm4B-4hzsA: undetectable	4mm4B-4hzsA: 21.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	None	0.57A	4mxxB-4hzsA: 20.9	4mxxB-4hzsA: 37.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0S_A_ADNA500_1 (AURORA KINASE A)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 11	LEU A 132 GLY A 133 VAL A 140 ALA A 156 LYS A 158 ASN A 257 LEU A 259 ASP A 270	None	0.86A	4o0sA-4hzsA: 23.5	4o0sA-4hzsA: 26.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0U_A_ADNA501_1 (AURORA KINASE A)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	4 / 6	VAL A 140 ALA A 156 LYS A 158 LEU A 259	None	0.60A	4o0uA-4hzsA: 11.7	4o0uA-4hzsA: 26.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 VAL A 140 LYS A 158 THR A 205 GLY A 211 LEU A 259 ASP A 270	None	0.75A	4otwA-4hzsA: 24.9	4otwA-4hzsA: 36.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4R7I_A_STIA1001_1 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	VAL A 140 ALA A 156 LYS A 158 THR A 205 LEU A 259 GLY A 269	None	0.63A	4r7iA-4hzsA: 27.0	4r7iA-4hzsA: 32.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZ7_A_1E8A901_1 (CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 10	ALA A 156 LYS A 158 ILE A 190 THR A 205 LEU A 207	None	0.99A	4rz7A-4hzsA: 10.6	4rz7A-4hzsA: 17.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZ7_A_1E8A901_1 (CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 10	ALA A 156 LYS A 158 THR A 205 LEU A 207 LEU A 259	None	0.75A	4rz7A-4hzsA: 10.6	4rz7A-4hzsA: 17.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	ALA A 156 LYS A 158 THR A 205 SER A 212 GLY A 269	None	0.89A	4rzvA-4hzsA: 10.8	4rzvA-4hzsA: 28.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	ALA A 156 THR A 205 SER A 212 GLY A 269 PHE A 271	None	0.62A	4rzvA-4hzsA: 10.8	4rzvA-4hzsA: 28.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	VAL A 140 ALA A 156 THR A 205 SER A 212 GLY A 269 PHE A 271	None	0.84A	4rzvB-4hzsA: 27.1	4rzvB-4hzsA: 28.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TYJ_A_0LIA801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	4 / 6	LEU A 132 VAL A 140 ARG A 251 ILE A 268	None	0.56A	4tyjA-4hzsA: 27.6	4tyjA-4hzsA: 38.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_A_0LIA1776_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 9	LEU A 132 VAL A 140 LYS A 158 ILE A 190 ARG A 251 LEU A 259 ILE A 268	None	1.08A	4v01A-4hzsA: 27.5	4v01A-4hzsA: 33.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_B_0LIB1770_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 9	LEU A 132 VAL A 140 LYS A 158 ILE A 190 ARG A 251 LEU A 259 ILE A 268	None	0.96A	4v01B-4hzsA: 27.4	4v01B-4hzsA: 33.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_A_0LIA1772_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	4 / 8	LYS A 158 ILE A 190 LEU A 259 ILE A 268	None	0.71A	4v04A-4hzsA: 27.3	4v04A-4hzsA: 33.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_B_0LIB1771_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 10	LEU A 132 VAL A 140 LYS A 158 ILE A 190 ARG A 251 LEU A 259 LEU A 273	None	1.33A	4v04B-4hzsA: 27.4	4v04B-4hzsA: 33.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_B_0LIB1771_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 10	LEU A 132 VAL A 140 LYS A 158 ILE A 190 LEU A 259 ILE A 268 LEU A 273	None	1.21A	4v04B-4hzsA: 27.4	4v04B-4hzsA: 33.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WKQ_A_IREA1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 ALA A 156 LYS A 158 THR A 205 LEU A 207 GLY A 211 ASP A 215 LEU A 259	None	0.73A	4wkqA-4hzsA: 28.6	4wkqA-4hzsA: 36.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_A_1N1A601_1 (TYROSINE-PROTEIN KINASE ABL1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	None	0.54A	4xeyA-4hzsA: 28.1	4xeyA-4hzsA: 30.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	None	0.56A	4xeyB-4hzsA: 27.6	4xeyB-4hzsA: 30.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	VAL A 140 ALA A 156 LYS A 158 GLY A 269 ASP A 270 PHE A 271	None	1.10A	4xv2A-4hzsA: 27.1	4xv2A-4hzsA: 28.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269 PHE A 271	None	1.17A	4xv2A-4hzsA: 27.1	4xv2A-4hzsA: 28.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAA_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 9	LEU A 132 VAL A 140 ALA A 156 GLY A 211 LEU A 259 GLY A 269	None	0.38A	5aaaA-4hzsA: 28.7	5aaaA-4hzsA: 33.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAB_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 10	LEU A 132 VAL A 140 ALA A 156 LYS A 158 GLY A 211 LEU A 259 GLY A 269 ASP A 270	None	0.68A	5aabA-4hzsA: 28.6	5aabA-4hzsA: 33.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 10	LEU A 132 VAL A 140 ALA A 156 LYS A 158 GLY A 211 LEU A 259 GLY A 269	None	0.51A	5aacA-4hzsA: 28.2	5aacA-4hzsA: 33.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5BVW_A_1N1A1009_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 ILE A 190 THR A 205 GLY A 211 LEU A 259	None	0.86A	5bvwA-4hzsA: 20.5	5bvwA-4hzsA: 35.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269	None	0.70A	5cswA-4hzsA: 17.4	5cswA-4hzsA: 28.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269	None	0.66A	5cswB-4hzsA: 27.3	5cswB-4hzsA: 28.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_A_1N1A501_1 (PROTEIN-TYROSINE KINASE 6)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 LEU A 207 GLY A 269	None	0.84A	5h2uA-4hzsA: 23.8	5h2uA-4hzsA: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_A_1N1A501_1 (PROTEIN-TYROSINE KINASE 6)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 LEU A 207 GLY A 211 LEU A 259 GLY A 269	None	0.75A	5h2uA-4hzsA: 23.8	5h2uA-4hzsA: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269 ASP A 270	None	0.84A	5h2uB-4hzsA: 24.1	5h2uB-4hzsA: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	9 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 LEU A 207 GLY A 211 LEU A 259 GLY A 269 ASP A 270	None	0.71A	5h2uB-4hzsA: 24.1	5h2uB-4hzsA: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 ALA A 156 LYS A 158 THR A 205 GLY A 269 ASP A 270	None	0.71A	5h2uC-4hzsA: 23.9	5h2uC-4hzsA: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	LEU A 132 ALA A 156 THR A 205 GLY A 211 LEU A 259 GLY A 269 ASP A 270	None	0.59A	5h2uC-4hzsA: 23.9	5h2uC-4hzsA: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259 GLY A 269 ASP A 270	None	0.65A	5h2uD-4hzsA: 31.7	5h2uD-4hzsA: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 LEU A 207 GLY A 211 LEU A 259 ASP A 270	None	0.76A	5h2uD-4hzsA: 31.7	5h2uD-4hzsA: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HES_A_032A401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	ILE A 190 THR A 205 ALA A 208 ASP A 215 PHE A 271 GLY A 272	None	0.83A	5hesA-4hzsA: 13.7	5hesA-4hzsA: 33.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HES_A_032A401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	VAL A 140 ALA A 156 ILE A 190 THR A 205 ALA A 208 ASP A 215 PHE A 271	None	0.72A	5hesA-4hzsA: 13.7	5hesA-4hzsA: 33.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	VAL A 140 ALA A 156 LYS A 158 THR A 205 ALA A 208 ASP A 215 PHE A 271	None	0.75A	5hesB-4hzsA: 25.5	5hesB-4hzsA: 33.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	ALA A 156 LYS A 158 THR A 205 LEU A 243 HIS A 250 GLY A 269	None	0.72A	5hi2A-4hzsA: 25.4	5hi2A-4hzsA: 29.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	GLY A 135 VAL A 140 ALA A 156 LYS A 158 THR A 205	None	0.54A	5hieA-4hzsA: 25.7	5hieA-4hzsA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269	None	0.66A	5hieA-4hzsA: 25.7	5hieA-4hzsA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	GLY A 135 VAL A 140 ALA A 156 LYS A 158 THR A 205	None	0.55A	5hieB-4hzsA: 25.7	5hieB-4hzsA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269	None	0.67A	5hieB-4hzsA: 25.7	5hieB-4hzsA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	GLY A 133 GLY A 135 VAL A 140 ALA A 156 LYS A 158 THR A 205	None	0.69A	5hieC-4hzsA: 19.4	5hieC-4hzsA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	GLY A 133 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269	None	0.73A	5hieC-4hzsA: 19.4	5hieC-4hzsA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	GLY A 135 VAL A 140 ALA A 156 LYS A 158 THR A 205	None	0.55A	5hieD-4hzsA: 25.5	5hieD-4hzsA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269	None	0.67A	5hieD-4hzsA: 25.5	5hieD-4hzsA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	ALA A 156 LEU A 189 PHE A 248 HIS A 250 LEU A 259	None	0.66A	5mo4A-4hzsA: 19.5	5mo4A-4hzsA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	GLY A 135 VAL A 140 ALA A 156 LYS A 158 MET A 181 THR A 205 PHE A 271	None	0.60A	5p9iA-4hzsA: 31.0	5p9iA-4hzsA: 33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	GLY A 138 VAL A 140 ALA A 156 LYS A 158 MET A 181 THR A 205 PHE A 271	None	1.45A	5p9iA-4hzsA: 31.0	5p9iA-4hzsA: 33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	VAL A 140 ALA A 156 MET A 181 THR A 205 GLY A 211 LEU A 259 PHE A 271	None	0.53A	5p9iA-4hzsA: 31.0	5p9iA-4hzsA: 33.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5TWJ_C_SAMC201_0 (RIBOSOMAL RNA LARGE SUBUNIT METHYLTRANSFERASE H)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 12	ASP A 146 ILE A 121 GLY A 122 SER A 154 VAL A 204	None	1.08A	5twjC-4hzsA: undetectable	5twjC-4hzsA: 15.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y80_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 VAL A 140 ALA A 156 THR A 205 LEU A 207 GLY A 211 LEU A 259 ASP A 270	None	0.80A	5y80A-4hzsA: 19.9	5y80A-4hzsA: 14.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YF9_X_NIOX401_1 (CASEIN KINASE II SUBUNIT ALPHA')	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 9	LEU A 132 VAL A 140 LYS A 158 ILE A 190 ASP A 270	None	1.13A	5yf9X-4hzsA: 20.1	5yf9X-4hzsA: 13.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_A_1E8A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	LEU A 132 GLY A 133 VAL A 140 ALA A 156 LYS A 158 MET A 181 LEU A 259 ASP A 270	None	0.81A	5yu9A-4hzsA: 31.0	5yu9A-4hzsA: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_B_1E8B1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	GLY A 133 VAL A 140 ALA A 156 LYS A 158 MET A 181 ASP A 215 LEU A 259 ASP A 270	None	0.76A	5yu9B-4hzsA: 31.3	5yu9B-4hzsA: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_C_1E8C1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	VAL A 140 ALA A 156 LYS A 158 MET A 181 GLY A 211 ASP A 215 ASP A 270	None	0.75A	5yu9C-4hzsA: 31.0	5yu9C-4hzsA: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_D_1E8D1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	7 / 12	VAL A 140 ALA A 156 LYS A 158 MET A 181 ASP A 215 ASP A 270 LEU A 273	None	0.78A	5yu9D-4hzsA: 31.8	5yu9D-4hzsA: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_D_1E8D1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	8 / 12	VAL A 140 ALA A 156 MET A 181 GLY A 211 ASP A 215 LEU A 259 ASP A 270 LEU A 273	None	0.63A	5yu9D-4hzsA: 31.8	5yu9D-4hzsA: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_B_LEVB801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	6 / 12	LEU A 132 VAL A 140 ALA A 156 LYS A 158 ALA A 208 GLY A 211	None	0.63A	5zv2B-4hzsA: 22.0	5zv2B-4hzsA: 15.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6FGC_A_D95A816_0 (GEPHYRIN)	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	5 / 11	PHE A 271 ILE A 268 LEU A 243 LEU A 192 MET A 203	None	1.50A	6fgcA-4hzsA: undetectable	6fgcA-4hzsA: 13.65

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1A7Y_A_DVAA2_0","ACTINOMYCIN D","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",4,"THR A 391;PRO A 390;THR A 414;PRO A 357","None","1.27A","1a7yA-4hzsA:undetectable;1a7yC-4hzsA:undetectable","1a7yA-4hzsA:5.99;1a7yC-4hzsA:5.99"],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.51A","1iepA-4hzsA:27.6","1iepA-4hzsA:38.65"],["1M17_A_AQ4A999_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;ALA A 156;LYS A 158;THR A 205;LEU A 207;GLY A 211;LEU A 259;ASP A 270","None","0.72A","1m17A-4hzsA:28.8","1m17A-4hzsA:35.98"],["1MUO_A_ADNA1_1","AURORA-RELATED KINASE 1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;GLY A 133;VAL A 140;ALA A 156;ALA A 208;LEU A 259","None","0.63A","1muoA-4hzsA:16.5","1muoA-4hzsA:26.32"],["1SQ5_B_PAUB6003_0","PANTOTHENATE KINASE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"GLY A 436;HIS A 223;TYR A 326;LEU A 405;ILE A 416","None","1.48A","1sq5B-4hzsA:undetectable","1sq5B-4hzsA:22.22"],["1T46_A_STIA3_1","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","None","0.58A","1t46A-4hzsA:20.7","1t46A-4hzsA:34.55"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"ALA A 156;THR A 205;LEU A 243;HIS A 250;GLY A 269","None","0.64A","1uwhA-4hzsA:26.1","1uwhA-4hzsA:29.31"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"ALA A 156;LYS A 158;THR A 205;LEU A 243;HIS A 250;GLY A 269","None","0.73A","1uwhB-4hzsA:25.9","1uwhB-4hzsA:29.31"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;THR A 205;LEU A 243;HIS A 250;GLY A 269","None","0.55A","1uwjA-4hzsA:10.8","1uwjA-4hzsA:29.31"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;THR A 205;LEU A 243;HIS A 250;GLY A 269","None","0.54A","1uwjB-4hzsA:10.8","1uwjB-4hzsA:29.31"],["1XBB_A_STIA1_1","TYROSINE-PROTEIN KINASE SYK","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;ALA A 208;GLY A 211;LEU A 259","None","0.35A","1xbbA-4hzsA:29.7","1xbbA-4hzsA:32.66"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"ALA A 156;MET A 181;THR A 205;GLY A 211;LEU A 214;ASP A 215;ARG A 218;ASP A 270;PHE A 271","None","0.95A","1xkkA-4hzsA:21.6","1xkkA-4hzsA:36.39"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"ALA A 156;THR A 205;GLY A 211;LEU A 214;ASP A 215;ARG A 218;LEU A 259;ASP A 270;PHE A 271","None","0.88A","1xkkA-4hzsA:21.6","1xkkA-4hzsA:36.39"],["1XKK_A_FMMA91_2","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;LYS A 158;LEU A 192;LEU A 207;LEU A 273","None","0.70A","1xkkA-4hzsA:21.6","1xkkA-4hzsA:36.39"],["2ITO_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;ALA A 156;LYS A 158;THR A 205;GLY A 211;ASP A 215;LEU A 259","None","0.63A","2itoA-4hzsA:29.3","2itoA-4hzsA:36.02"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;GLY A 133;VAL A 140;ALA A 156;LYS A 158;GLY A 211;LEU A 259;ASP A 270","None","0.71A","2ityA-4hzsA:29.4","2ityA-4hzsA:36.31"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;GLY A 133;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","None","0.73A","2ityA-4hzsA:29.4","2ityA-4hzsA:36.31"],["2ITZ_A_IREA2021_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;GLY A 211;ASP A 215;LEU A 259;ASP A 270","None","0.53A","2itzA-4hzsA:22.9","2itzA-4hzsA:36.02"],["2ITZ_A_IREA2021_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;ASP A 215;LEU A 259","None","0.66A","2itzA-4hzsA:22.9","2itzA-4hzsA:36.02"],["2XP2_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;GLY A 211;LEU A 259;GLY A 269","None","0.38A","2xp2A-4hzsA:28.8","2xp2A-4hzsA:33.88"],["2Y7J_C_B49C1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;ILE A 190;GLY A 211;ASP A 215;LEU A 259","None","0.72A","2y7jC-4hzsA:22.2","2y7jC-4hzsA:21.09"],["2Y7J_C_B49C1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;LEU A 207;GLY A 211;ASP A 215;LEU A 259","None","0.66A","2y7jC-4hzsA:22.2","2y7jC-4hzsA:21.09"],["2Y7J_D_B49D1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;ILE A 190;GLY A 211;ASP A 215;LEU A 259","None","0.66A","2y7jD-4hzsA:22.4","2y7jD-4hzsA:21.09"],["2Y7J_D_B49D1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;LEU A 207;GLY A 211;ASP A 215;LEU A 259","None","0.58A","2y7jD-4hzsA:22.4","2y7jD-4hzsA:21.09"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;ALA A 156;LYS A 158;LEU A 207;GLY A 211;LEU A 259","None","0.66A","3aoxA-4hzsA:19.4","3aoxA-4hzsA:32.66"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"VAL A 140;ALA A 156;MET A 181;LEU A 192;GLY A 211;LEU A 259;ASP A 270;PHE A 271;LEU A 273","None","0.53A","3bbtB-4hzsA:23.7","3bbtB-4hzsA:36.31"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"VAL A 140;ALA A 156;MET A 181;LEU A 192;LEU A 207;GLY A 211;LEU A 259;ASP A 270;LEU A 273","None","0.73A","3bbtB-4hzsA:23.7","3bbtB-4hzsA:36.31"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"VAL A 140;ALA A 156;MET A 181;LEU A 192;THR A 205;GLY A 211;LEU A 259;ASP A 270;PHE A 271","None","0.69A","3bbtB-4hzsA:23.7","3bbtB-4hzsA:36.31"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"VAL A 140;ALA A 156;MET A 181;LEU A 192;THR A 205;LEU A 207;GLY A 211;LEU A 259;ASP A 270","None","0.84A","3bbtB-4hzsA:23.7","3bbtB-4hzsA:36.31"],["3BBT_D_FMMD91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"VAL A 140;ALA A 156;LYS A 158;GLY A 211;LEU A 259;ASP A 270;PHE A 271;LEU A 273","None","0.65A","3bbtD-4hzsA:23.2","3bbtD-4hzsA:36.31"],["3BBT_D_FMMD91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"VAL A 140;ALA A 156;MET A 181;THR A 205;GLY A 211;LEU A 259;ASP A 270;PHE A 271;LEU A 273","None","0.85A","3bbtD-4hzsA:23.2","3bbtD-4hzsA:36.31"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;GLY A 133;ALA A 156;LYS A 158;GLY A 211;LEU A 259","None","0.47A","3c7qA-4hzsA:27.2","3c7qA-4hzsA:31.30"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"ALA A 156;LEU A 189;GLY A 211;PHE A 248;HIS A 250;LEU A 259","None","0.61A","3cs9A-4hzsA:27.5","3cs9A-4hzsA:35.59"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"ALA A 156;LEU A 189;GLY A 211;PHE A 248;HIS A 250","None","0.50A","3cs9D-4hzsA:26.6","3cs9D-4hzsA:35.59"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"ALA A 156;LEU A 189;THR A 205;GLY A 211;HIS A 250","None","0.64A","3cs9D-4hzsA:26.6","3cs9D-4hzsA:35.59"],["3EYG_A_MI1A1_1","TYROSINE-PROTEIN KINASE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"LEU A 132;GLY A 133;GLY A 135;GLY A 138;VAL A 140;ALA A 156;LYS A 158;SER A 212;LEU A 259","None","0.80A","3eygA-4hzsA:27.1","3eygA-4hzsA:31.18"],["3EYG_A_MI1A1_1","TYROSINE-PROTEIN KINASE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"LEU A 132;GLY A 135;GLY A 138;VAL A 140;ALA A 156;LYS A 158;SER A 212;ASN A 257;LEU A 259","None","0.97A","3eygA-4hzsA:27.1","3eygA-4hzsA:31.18"],["3G0E_A_B49A9000_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.58A","3g0eA-4hzsA:26.0","3g0eA-4hzsA:32.86"],["3G0F_A_B49A9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.62A","3g0fA-4hzsA:18.4","3g0fA-4hzsA:32.86"],["3G0F_B_B49B9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.57A","3g0fB-4hzsA:27.1","3g0fB-4hzsA:32.86"],["3MS9_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.46A","3ms9B-4hzsA:27.2","3ms9B-4hzsA:38.65"],["3MSS_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.54A","3mssB-4hzsA:27.4","3mssB-4hzsA:38.65"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","None","0.60A","3octA-4hzsA:27.4","3octA-4hzsA:32.75"],["3OHT_A_1N1A1000_1","P38A","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"GLY A 133;VAL A 140;ALA A 156;ILE A 190;THR A 205;LEU A 259","None","1.00A","3ohtA-4hzsA:5.2","3ohtA-4hzsA:24.74"],["3OHT_A_1N1A1000_1","P38A","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"GLY A 133;VAL A 140;ALA A 156;LYS A 158;ILE A 190;THR A 205","None","0.77A","3ohtA-4hzsA:5.2","3ohtA-4hzsA:24.74"],["3OHT_A_1N1A1000_1","P38A","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"GLY A 133;VAL A 140;ALA A 156;LYS A 158;THR A 205;ASP A 270","None","0.77A","3ohtA-4hzsA:5.2","3ohtA-4hzsA:24.74"],["3OHT_B_1N1B1000_1","P38A","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"GLY A 133;VAL A 140;ALA A 156;THR A 205;GLY A 211","None","0.53A","3ohtB-4hzsA:4.9","3ohtB-4hzsA:24.74"],["3QLG_B_1N1B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259;ASP A 270","None","0.62A","3qlgB-4hzsA:20.0","3qlgB-4hzsA:36.89"],["3QPS_A_CHDA211_0","CMER","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"LEU A 258;PHE A 378;ALA A 237;GLY A 239;ILE A 268","None","1.39A","3qpsA-4hzsA:undetectable","3qpsA-4hzsA:17.53"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.40A","3sxrA-4hzsA:16.7","3sxrA-4hzsA:39.86"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.38A","3sxrB-4hzsA:27.6","3sxrB-4hzsA:39.86"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;LEU A 207;GLY A 211;ASP A 215;LEU A 259","None","0.64A","3ug2A-4hzsA:23.3","3ug2A-4hzsA:35.31"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"LEU A 132;VAL A 140;ALA A 156;GLY A 211;PHE A 271","None","0.50A","3wzdA-4hzsA:28.3","3wzdA-4hzsA:33.53"],["3ZBF_A_VGHA3000_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;ALA A 156;LEU A 207;GLY A 211;LEU A 259;GLY A 269","None","0.58A","3zbfA-4hzsA:28.6","3zbfA-4hzsA:33.52"],["4AGC_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;GLY A 211;LEU A 259","None","0.43A","4agcA-4hzsA:27.0","4agcA-4hzsA:30.81"],["4DU2_B_LDPB501_1","CYTOCHROME P450 BM3 VARIANT B7","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",4,"ALA A 298;ALA A 369;ALA A 310;THR A 313","None","0.79A","4du2B-4hzsA:undetectable","4du2B-4hzsA:23.34"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259;ASP A 270","None","0.70A","4hjoA-4hzsA:32.4","4hjoA-4hzsA:35.85"],["4I22_A_IREA9001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"LEU A 132;GLY A 133;VAL A 140;ALA A 156;LYS A 158;GLY A 211;ASP A 215;LEU A 259;ASP A 270","None","0.67A","4i22A-4hzsA:24.8","4i22A-4hzsA:35.53"],["4IFG_A_1E8A601_1","CALMODULIN-DOMAIN PROTEIN KINASE 1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"GLY A 133;VAL A 140;ALA A 156;LYS A 158;LEU A 192;LEU A 259;LEU A 273","None","0.74A","4ifgA-4hzsA:23.6","4ifgA-4hzsA:24.55"],["4LMN_A_EUIA503_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"LYS A 158;ASN A 257;ASP A 270;PHE A 271;GLY A 272","None","0.84A","4lmnA-4hzsA:23.4","4lmnA-4hzsA:25.75"],["4MKC_A_4MKA1503_1","ALK TYROSINE KINASE RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"LEU A 132;GLY A 135;VAL A 140;ALA A 156;LYS A 158;LEU A 207;GLY A 211;LEU A 259;ASP A 270","None","0.85A","4mkcA-4hzsA:28.8","4mkcA-4hzsA:33.16"],["4MM4_B_8PRB603_2","TRANSPORTER","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",3,"SER A 311;MET A 315;ASP A 344","None","0.93A","4mm4B-4hzsA:undetectable","4mm4B-4hzsA:21.67"],["4MXX_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","None","0.57A","4mxxB-4hzsA:20.9","4mxxB-4hzsA:37.20"],["4O0S_A_ADNA500_1","AURORA KINASE A","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;GLY A 133;VAL A 140;ALA A 156;LYS A 158;ASN A 257;LEU A 259;ASP A 270","None","0.86A","4o0sA-4hzsA:23.5","4o0sA-4hzsA:26.72"],["4O0U_A_ADNA501_1","AURORA KINASE A","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",4,"VAL A 140;ALA A 156;LYS A 158;LEU A 259","None","0.60A","4o0uA-4hzsA:11.7","4o0uA-4hzsA:26.44"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;LYS A 158;THR A 205;GLY A 211;LEU A 259;ASP A 270","None","0.75A","4otwA-4hzsA:24.9","4otwA-4hzsA:36.02"],["4R7I_A_STIA1001_1","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;LYS A 158;THR A 205;LEU A 259;GLY A 269","None","0.63A","4r7iA-4hzsA:27.0","4r7iA-4hzsA:32.85"],["4RZ7_A_1E8A901_1","CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"ALA A 156;LYS A 158;ILE A 190;THR A 205;LEU A 207","None","0.99A","4rz7A-4hzsA:10.6","4rz7A-4hzsA:17.98"],["4RZ7_A_1E8A901_1","CGMP-DEPENDENT PROTEIN KINASE, PUTATIVE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"ALA A 156;LYS A 158;THR A 205;LEU A 207;LEU A 259","None","0.75A","4rz7A-4hzsA:10.6","4rz7A-4hzsA:17.98"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"ALA A 156;LYS A 158;THR A 205;SER A 212;GLY A 269","None","0.89A","4rzvA-4hzsA:10.8","4rzvA-4hzsA:28.15"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"ALA A 156;THR A 205;SER A 212;GLY A 269;PHE A 271","None","0.62A","4rzvA-4hzsA:10.8","4rzvA-4hzsA:28.15"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;THR A 205;SER A 212;GLY A 269;PHE A 271","None","0.84A","4rzvB-4hzsA:27.1","4rzvB-4hzsA:28.15"],["4TYJ_A_0LIA801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",4,"LEU A 132;VAL A 140;ARG A 251;ILE A 268","None","0.56A","4tyjA-4hzsA:27.6","4tyjA-4hzsA:38.87"],["4V01_A_0LIA1776_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;LYS A 158;ILE A 190;ARG A 251;LEU A 259;ILE A 268","None","1.08A","4v01A-4hzsA:27.5","4v01A-4hzsA:33.51"],["4V01_B_0LIB1770_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;LYS A 158;ILE A 190;ARG A 251;LEU A 259;ILE A 268","None","0.96A","4v01B-4hzsA:27.4","4v01B-4hzsA:33.51"],["4V04_A_0LIA1772_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",4,"LYS A 158;ILE A 190;LEU A 259;ILE A 268","None","0.71A","4v04A-4hzsA:27.3","4v04A-4hzsA:33.51"],["4V04_B_0LIB1771_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;LYS A 158;ILE A 190;ARG A 251;LEU A 259;LEU A 273","None","1.33A","4v04B-4hzsA:27.4","4v04B-4hzsA:33.51"],["4V04_B_0LIB1771_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;LYS A 158;ILE A 190;LEU A 259;ILE A 268;LEU A 273","None","1.21A","4v04B-4hzsA:27.4","4v04B-4hzsA:33.51"],["4WKQ_A_IREA1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;ALA A 156;LYS A 158;THR A 205;LEU A 207;GLY A 211;ASP A 215;LEU A 259","None","0.73A","4wkqA-4hzsA:28.6","4wkqA-4hzsA:36.00"],["4XEY_A_1N1A601_1","TYROSINE-PROTEIN KINASE ABL1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","None","0.54A","4xeyA-4hzsA:28.1","4xeyA-4hzsA:30.28"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","None","0.56A","4xeyB-4hzsA:27.6","4xeyB-4hzsA:30.28"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;LYS A 158;GLY A 269;ASP A 270;PHE A 271","None","1.10A","4xv2A-4hzsA:27.1","4xv2A-4hzsA:28.36"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269;PHE A 271","None","1.17A","4xv2A-4hzsA:27.1","4xv2A-4hzsA:28.36"],["5AAA_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;GLY A 211;LEU A 259;GLY A 269","None","0.38A","5aaaA-4hzsA:28.7","5aaaA-4hzsA:33.61"],["5AAB_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;GLY A 211;LEU A 259;GLY A 269;ASP A 270","None","0.68A","5aabA-4hzsA:28.6","5aabA-4hzsA:33.61"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;GLY A 211;LEU A 259;GLY A 269","None","0.51A","5aacA-4hzsA:28.2","5aacA-4hzsA:33.88"],["5BVW_A_1N1A1009_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;ILE A 190;THR A 205;GLY A 211;LEU A 259","None","0.86A","5bvwA-4hzsA:20.5","5bvwA-4hzsA:35.69"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269","None","0.70A","5cswA-4hzsA:17.4","5cswA-4hzsA:28.36"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269","None","0.66A","5cswB-4hzsA:27.3","5cswB-4hzsA:28.36"],["5H2U_A_1N1A501_1","PROTEIN-TYROSINE KINASE 6","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;LEU A 207;GLY A 269","None","0.84A","5h2uA-4hzsA:23.8","5h2uA-4hzsA:34.51"],["5H2U_A_1N1A501_1","PROTEIN-TYROSINE KINASE 6","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;THR A 205;LEU A 207;GLY A 211;LEU A 259;GLY A 269","None","0.75A","5h2uA-4hzsA:23.8","5h2uA-4hzsA:34.51"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269;ASP A 270","None","0.84A","5h2uB-4hzsA:24.1","5h2uB-4hzsA:34.51"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",9,"LEU A 132;VAL A 140;ALA A 156;THR A 205;LEU A 207;GLY A 211;LEU A 259;GLY A 269;ASP A 270","None","0.71A","5h2uB-4hzsA:24.1","5h2uB-4hzsA:34.51"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;ALA A 156;LYS A 158;THR A 205;GLY A 269;ASP A 270","None","0.71A","5h2uC-4hzsA:23.9","5h2uC-4hzsA:34.51"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"LEU A 132;ALA A 156;THR A 205;GLY A 211;LEU A 259;GLY A 269;ASP A 270","None","0.59A","5h2uC-4hzsA:23.9","5h2uC-4hzsA:34.51"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259;GLY A 269;ASP A 270","None","0.65A","5h2uD-4hzsA:31.7","5h2uD-4hzsA:34.51"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;THR A 205;LEU A 207;GLY A 211;LEU A 259;ASP A 270","None","0.76A","5h2uD-4hzsA:31.7","5h2uD-4hzsA:34.51"],["5HES_A_032A401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"ILE A 190;THR A 205;ALA A 208;ASP A 215;PHE A 271;GLY A 272","None","0.83A","5hesA-4hzsA:13.7","5hesA-4hzsA:33.24"],["5HES_A_032A401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"VAL A 140;ALA A 156;ILE A 190;THR A 205;ALA A 208;ASP A 215;PHE A 271","None","0.72A","5hesA-4hzsA:13.7","5hesA-4hzsA:33.24"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"VAL A 140;ALA A 156;LYS A 158;THR A 205;ALA A 208;ASP A 215;PHE A 271","None","0.75A","5hesB-4hzsA:25.5","5hesB-4hzsA:33.24"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"ALA A 156;LYS A 158;THR A 205;LEU A 243;HIS A 250;GLY A 269","None","0.72A","5hi2A-4hzsA:25.4","5hi2A-4hzsA:29.53"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"GLY A 135;VAL A 140;ALA A 156;LYS A 158;THR A 205","None","0.54A","5hieA-4hzsA:25.7","5hieA-4hzsA:29.94"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269","None","0.66A","5hieA-4hzsA:25.7","5hieA-4hzsA:29.94"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"GLY A 135;VAL A 140;ALA A 156;LYS A 158;THR A 205","None","0.55A","5hieB-4hzsA:25.7","5hieB-4hzsA:29.94"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269","None","0.67A","5hieB-4hzsA:25.7","5hieB-4hzsA:29.94"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"GLY A 133;GLY A 135;VAL A 140;ALA A 156;LYS A 158;THR A 205","None","0.69A","5hieC-4hzsA:19.4","5hieC-4hzsA:29.94"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"GLY A 133;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269","None","0.73A","5hieC-4hzsA:19.4","5hieC-4hzsA:29.94"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"GLY A 135;VAL A 140;ALA A 156;LYS A 158;THR A 205","None","0.55A","5hieD-4hzsA:25.5","5hieD-4hzsA:29.94"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269","None","0.67A","5hieD-4hzsA:25.5","5hieD-4hzsA:29.94"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"ALA A 156;LEU A 189;PHE A 248;HIS A 250;LEU A 259","None","0.66A","5mo4A-4hzsA:19.5","5mo4A-4hzsA:25.00"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"GLY A 135;VAL A 140;ALA A 156;LYS A 158;MET A 181;THR A 205;PHE A 271","None","0.60A","5p9iA-4hzsA:31.0","5p9iA-4hzsA:33.63"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"GLY A 138;VAL A 140;ALA A 156;LYS A 158;MET A 181;THR A 205;PHE A 271","None","1.45A","5p9iA-4hzsA:31.0","5p9iA-4hzsA:33.63"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"VAL A 140;ALA A 156;MET A 181;THR A 205;GLY A 211;LEU A 259;PHE A 271","None","0.53A","5p9iA-4hzsA:31.0","5p9iA-4hzsA:33.63"],["5TWJ_C_SAMC201_0","RIBOSOMAL RNA LARGE SUBUNIT METHYLTRANSFERASE H","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"ASP A 146;ILE A 121;GLY A 122;SER A 154;VAL A 204","None","1.08A","5twjC-4hzsA:undetectable","5twjC-4hzsA:15.69"],["5Y80_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;VAL A 140;ALA A 156;THR A 205;LEU A 207;GLY A 211;LEU A 259;ASP A 270","None","0.80A","5y80A-4hzsA:19.9","5y80A-4hzsA:14.11"],["5YF9_X_NIOX401_1","CASEIN KINASE II SUBUNIT ALPHA'","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"LEU A 132;VAL A 140;LYS A 158;ILE A 190;ASP A 270","None","1.13A","5yf9X-4hzsA:20.1","5yf9X-4hzsA:13.49"],["5YU9_A_1E8A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"LEU A 132;GLY A 133;VAL A 140;ALA A 156;LYS A 158;MET A 181;LEU A 259;ASP A 270","None","0.81A","5yu9A-4hzsA:31.0","5yu9A-4hzsA:13.99"],["5YU9_B_1E8B1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"GLY A 133;VAL A 140;ALA A 156;LYS A 158;MET A 181;ASP A 215;LEU A 259;ASP A 270","None","0.76A","5yu9B-4hzsA:31.3","5yu9B-4hzsA:13.99"],["5YU9_C_1E8C1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"VAL A 140;ALA A 156;LYS A 158;MET A 181;GLY A 211;ASP A 215;ASP A 270","None","0.75A","5yu9C-4hzsA:31.0","5yu9C-4hzsA:13.99"],["5YU9_D_1E8D1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",7,"VAL A 140;ALA A 156;LYS A 158;MET A 181;ASP A 215;ASP A 270;LEU A 273","None","0.78A","5yu9D-4hzsA:31.8","5yu9D-4hzsA:13.99"],["5YU9_D_1E8D1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",8,"VAL A 140;ALA A 156;MET A 181;GLY A 211;ASP A 215;LEU A 259;ASP A 270;LEU A 273","None","0.63A","5yu9D-4hzsA:31.8","5yu9D-4hzsA:13.99"],["5ZV2_B_LEVB801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",6,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;ALA A 208;GLY A 211","None","0.63A","5zv2B-4hzsA:22.0","5zv2B-4hzsA:15.03"],["6FGC_A_D95A816_0","GEPHYRIN","4hzs","ACTIVATED CDC42 KINASE 1","Homo sapiens",5,"PHE A 271;ILE A 268;LEU A 243;LEU A 192;MET A 203","None","1.50A","6fgcA-4hzsA:undetectable","6fgcA-4hzsA:13.65"]]